Hims & Hers Health Inc is a telehealth company based in San Francisco, California, providing a bridge between consumers and licensed healthcare professionals across the U.S., the U.K., and other countries. The company offers a wide array of health and wellness products and services, including both prescription and non-prescription options, directly to customers through its website and app. Its offerings span general wellness, sexual health, skincare, and hair care, featuring items like medications, supplements, cosmetics, and personal care devices. Additionally, Hims & Hers Health supports ongoing care with recurring prescriptions and medical consultations.
Hims and Hers Health heads into Q2 earnings carrying a brutal Q1 miss, margin compression, and a prediction market giving better than even odds on another stumble. Whether tonight's numbers vindicate the…
Thomas Richmond Hims and Hers has 2.6 million subscribers, a battered stock price, and a CEO buying shares instead of signaling an exit. That combination puts a very specific list of giants on alert,…
Scott Galloway and Ed Elson laid out the math on Prof G Markets and it should make every fast food shareholder uneasy: roughly 30 million Americans, about 1 in 8 US adults,…
Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector’s short history, and bargain hunters are circling the…
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing. That dislocation between share price and product…
Hims & Hers Health (NYSE:HIMS) absorbed another analyst downgrade. Bank of America cut its price objective on Hims & Hers stock to $30 from $32, while keeping a Neutral rating. The firm…
David Moadel Shares of Hims & Hers Health (NYSE:HIMS) are under pressure after JPMorgan trimmed its price target on the consumer telehealth name following a messy first quarter. The firm lowered its price target…
David Moadel Live Updates HIMS Q1 Earnings Coverage Wrap-Up4:25pm ETThat wraps up our initial coverage of Hims and Hers Health’s Q1 results. Thank you for stopping by! Check out management’s earnings call at 5…
Thomas Richmond Hims & Hers Health (NYSE:HIMS) just picked up a high-profile endorsement. JPMorgan analyst Cory Carpenter initiated coverage with an Overweight rating and a $35 price target, framing the telehealth platform’s recent Novo…
The GLP-1 weight-loss category exploded into a multi-billion-dollar opportunity that blends medication access with ongoing patient support. This morning, Amazon‘s (NASDAQ:AMZN | AMZN Price Prediction) One Medical platform rolled out a national…
Rich Duprey Hims & Hers Health (NYSE:HIMS) shares are up 9% in early trading Monday, climbing from $28.82 to $31 and change as investors pile into the stock ahead of a May 11 earnings…
The S&P 500 (^GSPC) crossed 7,000 for the first time in history this week, closing at 7,022.95 on Wednesday before pushing to 7,041.28 on Thursday. Futures are pointing higher Friday as President…
Hims & Hers Health (NYSE:HIMS) just got a fresh look from Bank of America, which raised its price target on the stock to $25 from $21 while maintaining a Neutral rating. The…
David Moadel Hims & Hers Health (NYSE:HIMS) looked like a fallen growth star earlier this year. The telehealth platform was hammered by the FDA’s aggressive crackdown on compounded GLP-1 drugs, complete with warning letters…
Rich Duprey Two healthcare names are drawing fresh analyst attention this week as Wall Street recalibrates around a landmark GLP-1 truce and a fertility benefits company navigating a murky 2026 outlook. Barclays analyst Glen…
